Navigation Links
Despite Decline in Share of Global Output, U.S. Science Impact Still Strong, Says Thomson Reuters
Date:1/28/2009

PHILADELPHIA and LONDON, Jan. 28 /PRNewswire/ -- The Scientific business of Thomson Reuters today announced the results of a study showing that the United States' share of scientific research output continues to shrink while Asia-Pacific's share of output rises. Nevertheless, the U.S. retains a healthy footing globally in the relative impact of its research.

In its January/February issue of Science Watch, Thomson Reuters analyzes 12 year's worth of data from its National Science Indicators database to determine the U.S.'s global scientific influence based on the nation's research output and impact.

In 2005, Science Watch noted that the U.S.'s output, as a percentage of world science, was in decline, with Asia-Pacific's output steadily rising. This latest analysis shows the trends continuing. In 2005, the U.S. contributed 32.8 percent of global research; by 2007 its share slid to 31.5 percent. During the same period, Asia-Pacific's share increased from 25.9 percent to 28.2 percent.

"It is important to note that measuring scientific output is only one way to measure a country's influence in the sciences," said Christopher King, editor of Science Watch. "Because citations are an acknowledgement of intellectual debt, we also evaluate a country's citation impact. The U.S.'s citation impact has remained strong in the major science fields."

In all 21 science fields analyzed for this report, the U.S. markedly surpassed the world average in citation impact. Topping the list was Physics, where the U.S. exceeded the world mark by 55 percent, followed by Chemistry and Materials Science where the U.S. exceeded the world by 52 percent and 47 percent, respectively.

For more information about U.S. research output and impact, including expert analysis, visit ScienceWatch.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Fadel Partners Announces 13% Growth Despite IT Services Industry Downtrend
2. Despite Economic Woes, Physician Compensation Increases
3. Investment and Growth in US Medical Technology Industry Continues Despite Challenging Public Markets
4. Multigene Test Predicts Who Could Avoid Chemotherapy Despite Positive Lymph Nodes in Early Breast Cancer
5. Cell Therapeutics Net Loss Declines as Operating Expenses Decrease By 58% in Third Quarter 2008
6. Data show a decline in cystic fibrosis since introduction of prenatal carrier screening
7. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
8. Progen Shareholders Call Meeting to Spill Progen Board and Offer Merger or Full Cash Back to Shareholders
9. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
10. IntraLinks Poll: Half of Clinical Trial Management Professionals Share Critical Information Via E-Mail
11. Cell Therapeutics, Inc. Provides Update on the Special Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 2014 At the request of the ... 60-day extension for the public comment period (Docket No. ... Model Aircraft established by Congress as part of the ... extension establishes the new deadline for comments as September ... Transportation/FAA notice published in the Federal Register on July ...
(Date:7/25/2014)... Sinovac Biotech Ltd. (Nasdaq: SVA ), a leading ... today announced that it will release its unaudited financial results ... close on Thursday, August 14, 2014 EDT. The Company will ... Friday, August 15, 2014, at 8:00 a.m. EDT (Friday, August ... the Company,s financial results and provide an update on recent ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... -- A novel combination of microscopy and data processing ... Ridge National Laboratory an unprecedented look at the surface ... electrochemical properties. , The research team led by ... of a perovskite manganite, a complex material that exhibits ... understand surface behavior could benefit researchers who are interested ...
Breaking Biology Technology:FAA Grants Comment Extension at the Request of AMA 2Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ORNL study reveals new characteristics of complex oxide surfaces 2
... Makes it Easy to Connect with Technology ... on Specific Chemical Reactions, PRINCETON, N.J., July ... portal for manufacturers that require service,and support in ... bio-technology products, industrial products and,higher-value chemicals. The all-new ...
... July 14 Vermillion, Inc.,(Nasdaq: VRML ), ... engaged ThinkPanmure LLC., a global, growth-company investment bank, ... alternatives,intended to enhance the potential of the Company,s ... biomarkers to,maximize stockholder value. No assurances can be ...
... Cardium Therapeutics,(Amex: CXM ) and its ... InnerCool,s RapidBlue(TM) endovascular temperature modulation,system conforms to ... use in,inducing, maintaining and reversing mild hypothermia ... arrest, neurosurgery, fever,cardiovascular re-warming, trauma re-warming, and ...
Cached Biology Technology:Informex365.com is Launched for Manufacturers in Search of Chemical Reactions Expertise 2Informex365.com is Launched for Manufacturers in Search of Chemical Reactions Expertise 3Vermillion Retains ThinkPanmure to Assist in the Evaluation of Potential Strategic Alternatives 2Cardium Announces InnerCool's New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification 2Cardium Announces InnerCool's New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification 3Cardium Announces InnerCool's New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification 4Cardium Announces InnerCool's New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification 5Cardium Announces InnerCool's New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification 6Cardium Announces InnerCool's New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification 7Cardium Announces InnerCool's New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification 8
(Date:7/24/2014)... Scientists at The New York Stem Cell ... to creating a viable cell replacement therapy for ... , For the first time, NYSCF scientists generated ... samples of patients with primary progressive multiple sclerosis ... induce these stem cells into becoming oligodendrocytes, the ...
(Date:7/24/2014)... many sobering examples of how wildlife loss leads to ... co-authored by Wildlife Conservation Society (WCS) Health & ... Golden, calls for an interdisciplinary approach to tackle global ... supports about 15% of the world,s people and provides ... poor. It should come as no surprise that today,s ...
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2New study draws links between wildlife loss and social conflicts 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... marketed as plant growth enhancers are becoming increasingly ... small companies with limited research capabilities, have not ... about product effectiveness been documented by scientific data. ... growth regulatory effect of Tea Seed Powder (TSP), ...
... in the adult human body are genetically identical, but develop ... or neurons, by activating some genes while inhibiting others. Remarkably, ... by remembering which genes should be kept on or off, ... is not written directly into the DNA, yet it is ...
... a defense against predators or pathogens. Some are also used ... in medicines. As recently as the early 1990s, a unique ... discovered. First noted through African tribal use as a ... since been determined to serve as a powerful insecticidal and ...
Cached Biology News:Plant growth affected by tea seed powder 2Making copies at the right time 2Making copies at the right time 3Cellular processing of proteins found in Congolese child birthing tea now revealed 2Cellular processing of proteins found in Congolese child birthing tea now revealed 3Cellular processing of proteins found in Congolese child birthing tea now revealed 4
... The Polymerase gene from Thermus aquaticus ... in E. coli, then highly purified ... is used in the amplification and ... The quality of the Taq DNA ...
... iTaq DNA polymerase is ... suitable for both conventional and ... is supplied at a concentration ... and includes 5,000 units polymerase, ...
Rabbit polyclonal to hnRNP-U...
... is an antibody-mediated hot-start DNA ... and real-time PCR applications. The ... concentration of 5 units per ... polymerase, 1.25 ml 10x PCR ...
Biology Products: